Emerging clinical applications of selected biomarkers in melanoma

References

• SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin201464192924399786
   PubMed Web of Science ®Google Scholar
• BalchCMGershenwaldJESoongSJFinal version of 2009 AJCC melanoma staging and classificationJ Clin Oncol200927366199620619917835
   PubMed Web of Science ®Google Scholar
• KozarewaIRosa-RosaJMWardellCPA modified method for whole exome resequencing from minimal amounts of starting DNAPLoS One201273e3261722403682
   PubMed Web of Science ®Google Scholar
• HodisEWatsonIRKryukovGVA landscape of driver mutations in melanomaCell2012150225126322817889
   PubMed Web of Science ®Google Scholar
• IbrahimNHaluskaFGMolecular pathogenesis of cutaneous melanocytic neoplasmsAnnu Rev Pathol2009455157919400696
   PubMed Web of Science ®Google Scholar
• KoJMFisherDEA new era: melanoma genetics and therapeuticsJ Pathol2011223224125021125678
   PubMed Web of Science ®Google Scholar
• DaviesHBignellGRCoxCMutations of the BRAF gene in human cancerNature2002417689294995412068308
   PubMed Web of Science ®Google Scholar
• XiaJJiaPHutchinsonKEA meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevanceMol Cancer Ther20141371918192824755198
   PubMed Web of Science ®Google Scholar
• WoodmanSELazarAJAldapeKDDaviesMANew strategies in melanoma: molecular testing in advanced diseaseClin Cancer Res20121851195120022275506
   PubMed Web of Science ®Google Scholar
• CurryJLTorres-CabalaCATetzlaffMTBowmanCPrietoVGMolecular platforms utilized to detect BRAF V600E mutation in melanomaSemin Cutan Med Surg201231426727323174497
   PubMed Web of Science ®Google Scholar
• SlominskiATobinDJShibaharaSWortsmanJMelanin pigmentation in mammalian skin and its hormonal regulationPhysiol Rev20048441155122815383650
   PubMed Web of Science ®Google Scholar
• SlominskiAZmijewskiMAPawelekJL-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functionsPigment Cell Melanoma Res2012251142721834848
   PubMed Web of Science ®Google Scholar
• SlominskiAWortsmanJPlonkaPMSchallreuterKUPausRTobinDJHair follicle pigmentationJ Invest Dermatol20051241132115654948
   PubMed Web of Science ®Google Scholar
• SlominskiAWortsmanJLugerTPausRSolomonSCorticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stressPhysiol Rev2000803979102010893429
   PubMed Web of Science ®Google Scholar
• SlominskiATZmijewskiMAZbytekBTobinDJTheoharidesTCRivierJKey role of CRF in the skin stress response systemEndocr Rev201334682788423939821
   PubMed Web of Science ®Google Scholar
• ChapmanPBHauschildARobertCBRIM-3 Study GroupImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• KeeDMcArthurGTargeted therapies for cutaneous melanomaHematol Oncol Clin North Am201428349150524880943
   PubMed Web of Science ®Google Scholar
• MillerDMFlahertyKTTsaoHCurrent status and future directions of molecularly targeted therapies and immunotherapies for melanomaSemin Cutan Med Surg2014332606725085663
   PubMed Web of Science ®Google Scholar
• KwongLNDaviesMATargeted therapy for melanoma: rational combinatorial approachesOncogene20143311923416974
   PubMed Web of Science ®Google Scholar
• SolitDBRosenNResistance to BRAF inhibition in melanomasN Engl J Med2011364877277421345109
   PubMed Web of Science ®Google Scholar
• BucheitADDaviesMAEmerging insights into resistance to BRAF inhibitors in melanomaBiochem Pharmacol201487338138924291778
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• CooperZAJunejaVRSagePTResponse to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockadeCancer Immunol Res20142764365424903021
   PubMed Web of Science ®Google Scholar
• ChiMYeYZhangXDChenJInsulin induces drug resistance in melanoma through activation of the PI3K/Akt pathwayDrug Des Devel Ther20148255262
   Web of Science ®Google Scholar
• ChenJShaoRZhangXDChenCApplications of nanotechnology for melanoma treatment, diagnosis, and theranosticsInt J Nanomedicine201382677268823926430
   PubMed Web of Science ®Google Scholar
• KossLGMelamedMRKoss’ Diagnostic Cytology and Its Histopathologic Bases15th edPhiladelphia, PALippincott Williams & Wilkins2006
   Google Scholar
• TetzlaffMTWangWLMillessTLAmbiguous melanocytic tumors in a tertiary referral center: the contribution of fluorescence in situ hybridization (FISH) to conventional histopathologic and immunophenotypic analysesAm J Surg Pathol201337121783179624061523
   PubMed Web of Science ®Google Scholar
• HemesathTJSteingrímssonEMcGillGmicrophthalmia, a critical factor in melanocyte development, defines a discrete transcription factor familyGenes Dev1994822277027807958932
   PubMed Web of Science ®Google Scholar
• FuseNYasumotoKSuzukiHTakahashiKShibaharaSIdentification of a melanocyte-type promoter of the microphthalmia-associated transcription factor geneBiochem Biophys Res Commun199621937027078645245
   PubMed Web of Science ®Google Scholar
• BentleyNJEisenTGodingCRMelanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiatorMol Cell Biol19941412799680067969139
   PubMed Web of Science ®Google Scholar
• YasumotoKYokoyamaKShibataKTomitaYShibaharaSMicrophthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase geneMol Cell Biol19941412805880707969144
   PubMed Web of Science ®Google Scholar
• GranterSRWeilbaecherKNQuigleyCFletcherCDFisherDEMicrophthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanomaAm J Dermatopathol200123318518911391097
   PubMed Web of Science ®Google Scholar
• MiettinenMFernandezMFranssilaKGatalicaZLasotaJSarlomo-RikalaMMicrophthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markersAm J Surg Pathol200125220521111176069
   PubMed Web of Science ®Google Scholar
• OrdóñezNGValue of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and updateHum Pathol201445219120523648379
   PubMed Web of Science ®Google Scholar
• WickMRSwansonPERocamoraARecognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumorsJ Cutan Pathol19881542012073053811
   PubMed Web of Science ®Google Scholar
• OhsieSJSarantopoulosGPCochranAJBinderSWImmunohistochemical characteristics of melanomaJ Cutan Pathol200835543344418399807
   PubMed Web of Science ®Google Scholar
• BusamKJIversenKCoplanKCJungbluthAAAnalysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanomaAm J Surg Pathol200125219720411176068
   PubMed Web of Science ®Google Scholar
• IvanDPrietoVGUse of immunohistochemistry in the diagnosis of melanocytic lesions: applications and pitfallsFuture Oncol2010671163117520624128
   PubMed Web of Science ®Google Scholar
• NybakkenGESargenMAbrahamRZhangPJMingMXuXMITF accurately highlights epidermal melanocytes in atypical intraepidermal melanocytic proliferationsAm J Dermatopathol2013351252922668579
   PubMed Web of Science ®Google Scholar
• PrietoVGSheaCRImmunohistochemistry of melanocytic proliferationsArch Pathol Lab Med2011135785385921732774
   PubMed Web of Science ®Google Scholar
• BeltraminelliHShabrawi-CaelenLEKerlHCerroniLMelan-a-positive “pseudomelanocytic nests”: a pitfall in the histopathologic and immunohistochemical diagnosis of pigmented lesions on sun-damaged skinAm J Dermatopathol200931330530819384076
   PubMed Web of Science ®Google Scholar
• BuonaccorsiJNPrietoVGTorres-CabalaCSusterSPlazaJADiagnostic utility and comparative immunohistochemical analysis of MITF-1 and SOX10 to distinguish melanoma in situ and actinic keratosis: a clinicopathological and immunohistochemical study of 70 casesAm J Dermatopathol201436212413023782678
   PubMed Web of Science ®Google Scholar
• KimJTaubeJMMcCalmontTHGlusacEJQuantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situJ Cutan Pathol2011381077577921797920
   PubMed Web of Science ®Google Scholar
• BlackWHTharejaSKBlakeBPChenRCherpelisBSGlassLFDistinction of melanoma in situ from solar lentigo on sun-damaged skin using morphometrics and MITF immunohistochemistryAm J Dermatopathol201133657357821697700
   PubMed Web of Science ®Google Scholar
• KieferJCBack to basics: Sox genesDev Dyn200723682356236617584862
   PubMed Web of Science ®Google Scholar
• PingaultVBondurandNKuhlbrodtKSOX10 mutations in patients with Waardenburg-Hirschsprung diseaseNat Genet19981821711739462749
   PubMed Web of Science ®Google Scholar
• LeeMGoodallJVerasteguiCBallottiRGodingCRDirect regulation of the Microphthalmia promoter by Sox10 links Waardenburg-Shah syndrome (WS4)-associated hypopigmentation and deafness to WS2J Biol Chem200027548379783798310973953
   PubMed Web of Science ®Google Scholar
• LudwigARehbergSWegnerMMelanocyte-specific expression of dopachrome tautomerase is dependent on synergistic gene activation by the Sox10 and Mitf transcription factorsFEBS Lett20045561–323624414706856
   PubMed Web of Science ®Google Scholar
• BondurandNPingaultVGoerichDEInteraction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndromeHum Mol Genet20009131907191710942418
   PubMed Web of Science ®Google Scholar
• NonakaDChiribogaLRubinBPSox10: a pan-schwannian and melanocytic markerAm J Surg Pathol20083291291129818636017
   PubMed Web of Science ®Google Scholar
• OrdóñezNGValue of SOX10 immunostaining in tumor diagnosisAdv Anat Pathol201320427528323752089
   PubMed Web of Science ®Google Scholar
• AgnarsdóttirMSoomanLBolanderASOX10 expression in superficial spreading and nodular malignant melanomasMelanoma Res201020646847820890226
   PubMed Web of Science ®Google Scholar
• KaramchandaniJRNielsenTOvan de RijnMWestRBSox10 and S100 in the diagnosis of soft-tissue neoplasmsAppl Immunohistochem Mol Morphol201220544545022495377
   PubMedGoogle Scholar
• Ramos-HerberthFIKaramchandaniJKimJDadrasSSSOX10 immunostaining distinguishes desmoplastic melanoma from excision scarJ Cutan Pathol201037994495220653825
   PubMed Web of Science ®Google Scholar
• BlochinENonakaDDiagnostic value of Sox10 immunohistochemical staining for the detection of metastatic melanoma in sentinel lymph nodesHistopathology200955562662819912373
   PubMed Web of Science ®Google Scholar
• KahnHJBaileyDMarksAMonoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi’s sarcoma and a subset of angiosarcomasMod Pathol200215443444011950918
   PubMed Web of Science ®Google Scholar
• NiakosariFKahnHJMarksAFromLDetection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40: a new selective immunohistochemical marker of lymphatic endotheliumArch Dermatol2005141444044415837861
   PubMedGoogle Scholar
• PeterssonFDiwanAHIvanDImmunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survivalJ Cutan Pathol200936111157116319222695
   PubMed Web of Science ®Google Scholar
• DoedenKMaZNarasimhanBSwetterSMDetmarMDadrasSSLymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasisJ Cutan Pathol200936777278019032379
   PubMed Web of Science ®Google Scholar
• WeberSKSauerwaldAPölcherMDetection of lymphovascular invasion by D2-40 (podoplanin) immunoexpression in endometrial cancerInt J Gynecol Cancer20122281442144822964524
   PubMed Web of Science ®Google Scholar
• LupinacciRMMelloESPinheiroRSIntrahepatic lymphatic invasion but not vascular invasion is a major prognostic factor after resection of colorectal cancer liver metastasesWorld J Surg20143882089209624663482
   PubMed Web of Science ®Google Scholar
• ImamuraYWatanabeMNagaiYLymphatic vessel invasion detected by the D2-40 monoclonal antibody is an independent prognostic factor in node-negative esophageal squamous cell carcinomaJ Surg Oncol2012105327728322271500
   PubMed Web of Science ®Google Scholar
• LeeJABaeJWWooSUKimHKimCHD2-40, Podoplanin, and CD31 as a prognostic predictor in invasive ductal carcinomas of the breastJ Breast Cancer201114210411121847404
   PubMed Web of Science ®Google Scholar
• KahnHJMarksAA new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumorsLab Invest20028291255125712218087
   PubMed Web of Science ®Google Scholar
• RoseAEChristosPJLackayeDClinical relevance of detection of lymphovascular invasion in primary melanoma using endothelial markers D2-40 and CD34Am J Surg Pathol201135101441144921881483
   PubMed Web of Science ®Google Scholar
• NielsenPSRiber-HansenRSteinicheTImmunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesionsAm J Dermatopathol201133436137021610457
   PubMed Web of Science ®Google Scholar
• RichardsHWMedranoEEEpigenetic marks in melanomaPigment Cell Melanoma Res2009221142919040501
   PubMed Web of Science ®Google Scholar
• JuanGTraganosFJamesWMHistone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosisCytometry199832271779627219
   PubMedGoogle Scholar
• SchimmingTTGrabellusFRonerMpHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomasAm J Dermatopathol201234326626922197861
   PubMed Web of Science ®Google Scholar
• TetzlaffMTCurryJLIvanDImmunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanomaMod Pathol20132691153116023558574
   PubMed Web of Science ®Google Scholar
• LadsteinRGBachmannIMStraumeOAkslenLAPrognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanomaJ Invest Dermatol201213241247125222297638
   PubMed Web of Science ®Google Scholar
• GershenwaldJESoongSJBalchCMAmerican Joint Committee on Cancer (AJCC) Melanoma Staging Committee2010 TNM staging system for cutaneous melanoma … and beyondAnn Surg Oncol20101761475147720300965
   PubMed Web of Science ®Google Scholar
• ThompsonJFSoongSJBalchCMPrognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging databaseJ Clin Oncol201129162199220521519009
   PubMed Web of Science ®Google Scholar
• IkenbergKPfaltzMRakozyCKempfWImmunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanomaJ Cutan Pathol201239332433022335591
   PubMed Web of Science ®Google Scholar
• MartinezDRRichardsHWLinQH3K79me3T80ph is a novel histone dual modification and a mitotic indicator in melanomaJ Skin Cancer2012201282353423227340
   PubMedGoogle Scholar
• HammondSLByrumSDNamjoshiSMitotic phosphorylation of histone H3 threonine 80Cell Cycle201413344045224275038
   PubMed Web of Science ®Google Scholar
• HendersonSATetzlaffMTPattanaprichakulPDetection of mitotic figures and G2+ tumor nuclei with histone markers correlates with worse overall survival in patients with Merkel cell carcinomaJ Cutan Pathol Epub9262014
   Web of Science ®Google Scholar
• DenisMGKhammariAValleeADetection of BRAF mutations in the plasma of melanoma patients as an early marker of treatment efficiencyJ Clin Oncol2014325s (Suppl; abstr 9069)
   Google Scholar
• CapperDBerghoffASvon DeimlingAPreusserMClinical neuropathology practice news 2-2012: BRAF V600E testingClin Neuropathol2012312646622385786
   PubMed Web of Science ®Google Scholar
• LongGVWilmottJSCapperDImmunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanomaAm J Surg Pathol2013371616523026937
   PubMed Web of Science ®Google Scholar
• ColombaEHélias-RodzewiczZVon DeimlingADetection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencingJ Mol Diagn20131519410023159108
   PubMed Web of Science ®Google Scholar
• BusamKJHedvatCPulitzerMvon DeimlingAJungbluthAAImmunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesionsAm J Surg Pathol201337341342023211290
   PubMed Web of Science ®Google Scholar
• JensenDERauscherFJBAP1, a candidate tumor suppressor protein that interacts with BRCA1Ann N Y Acad Sci199988619119410667217
   PubMed Web of Science ®Google Scholar
• AoudeLGWadtKBojesenAA BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancersPLoS One201388e7214423977234
   PubMed Web of Science ®Google Scholar
• WiesnerTObenaufACMuraliRGermline mutations in BAP1 predispose to melanocytic tumorsNat Genet201143101018102121874003
   PubMed Web of Science ®Google Scholar
• WiesnerTMuraliRFriedIA distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expressionAm J Surg Pathol201236681883022367297
   PubMed Web of Science ®Google Scholar
• ClarkeLEBessEMoyersKKolquistKARockCThe influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologistsJ Clin Oncol2014325s (Suppl; abstr TPS9111)
   Google Scholar
• SiroyAEBolandGMMiltonDRBeyond BRAF: clinical mutation panel testing by next-generation sequencing in advanced melanomaJ Invest Dermatol Epub8222014
   Web of Science ®Google Scholar